This study is the largest study until date conducted to examine the factors influencing the withholding of subsequent cytotoxic chemotherapy after failure of treatment with a first‐ or second‐generation EGFR‐TKI in consecutive EGFR‐mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.